JPWO2022154045A1 - - Google Patents
Info
- Publication number
- JPWO2022154045A1 JPWO2022154045A1 JP2022575626A JP2022575626A JPWO2022154045A1 JP WO2022154045 A1 JPWO2022154045 A1 JP WO2022154045A1 JP 2022575626 A JP2022575626 A JP 2022575626A JP 2022575626 A JP2022575626 A JP 2022575626A JP WO2022154045 A1 JPWO2022154045 A1 JP WO2022154045A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021003671 | 2021-01-13 | ||
| JP2021003671 | 2021-01-13 | ||
| PCT/JP2022/000891 WO2022154045A1 (ja) | 2021-01-13 | 2022-01-13 | 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022154045A1 true JPWO2022154045A1 (https=) | 2022-07-21 |
| JPWO2022154045A5 JPWO2022154045A5 (https=) | 2024-10-29 |
| JP7808059B2 JP7808059B2 (ja) | 2026-01-28 |
Family
ID=82448474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575626A Active JP7808059B2 (ja) | 2021-01-13 | 2022-01-13 | 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240288435A1 (https=) |
| EP (1) | EP4279606A4 (https=) |
| JP (1) | JP7808059B2 (https=) |
| KR (1) | KR20230131222A (https=) |
| CN (1) | CN116761895A (https=) |
| WO (1) | WO2022154045A1 (https=) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008539694A (ja) * | 2005-04-25 | 2008-11-20 | 国立大学法人山梨大学 | Ｃｌｅｃ−２シグナル伝達により止血疾患を治療するための組成物および方法 |
| WO2012128082A1 (ja) * | 2011-03-22 | 2012-09-27 | 公益財団法人がん研究会 | マウス抗Ａｇｇｒｕｓモノクローナル抗体 |
| JP2014070942A (ja) * | 2012-09-28 | 2014-04-21 | Mitsubishi Chemical Medience Corp | 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法 |
| WO2017027379A1 (en) * | 2015-08-07 | 2017-02-16 | Thomas Helledays Stiftelse För Medicinsk Forskning | Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2610910A1 (en) | 2005-06-09 | 2006-12-21 | Paul H. Mcpherson | Methods and compositions for the diagnosis of venous thromboembolic disease |
| FR3048001B1 (fr) | 2016-02-18 | 2018-02-09 | Diagnostica Stago | Methode de dosage des d-dimeres specifiques de la maladie thromboembolique veineuse |
| EP4113524A4 (en) * | 2020-02-28 | 2024-03-06 | LSI Medience Corporation | METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT |
-
2022
- 2022-01-13 EP EP22739450.9A patent/EP4279606A4/en active Pending
- 2022-01-13 CN CN202280009906.2A patent/CN116761895A/zh active Pending
- 2022-01-13 JP JP2022575626A patent/JP7808059B2/ja active Active
- 2022-01-13 US US18/261,155 patent/US20240288435A1/en active Pending
- 2022-01-13 KR KR1020237025829A patent/KR20230131222A/ko active Pending
- 2022-01-13 WO PCT/JP2022/000891 patent/WO2022154045A1/ja not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008539694A (ja) * | 2005-04-25 | 2008-11-20 | 国立大学法人山梨大学 | Ｃｌｅｃ−２シグナル伝達により止血疾患を治療するための組成物および方法 |
| WO2012128082A1 (ja) * | 2011-03-22 | 2012-09-27 | 公益財団法人がん研究会 | マウス抗Ａｇｇｒｕｓモノクローナル抗体 |
| JP2014070942A (ja) * | 2012-09-28 | 2014-04-21 | Mitsubishi Chemical Medience Corp | 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法 |
| WO2017027379A1 (en) * | 2015-08-07 | 2017-02-16 | Thomas Helledays Stiftelse För Medicinsk Forskning | Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma |
Non-Patent Citations (7)
| Title |
|---|
| NAZARI, P. M. S. ET AL.: "The role of podoplanin in cancer-associated thrombosis", THROMBOSIS RESEARCH, vol. 164, JPN6022006207, 2018, pages 34 - 39, ISSN: 0005711815 * |
| SHIRAI, T. ET AL.: "CLEC-2 facilitates hematogeneous tumor metastasis and in vitro tumor growth, but not in vivo tumor g", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 13, no. 2, JPN6022006208, June 2015 (2015-06-01), pages 226, ISSN: 0005711811 * |
| SUZUKI-INOUE K. ET AL.: "Roles of the CLEC-2-podoplanin interaction in tumor progression", PLATELETS, vol. 28, no. 8, JPN6022006209, 2018, pages 786 - 792, ISSN: 0005711812 * |
| SUZUKI-INOUE, K. ET AL.: "Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and", BLOOD, vol. 134, no. 22, JPN6022006210, 28 November 2019 (2019-11-28), pages 1912 - 1918, ISSN: 0005711813 * |
| 佐野誠 ほか: "血漿sVCAM-1とANP上昇は膵癌関連血栓症/血栓塞栓症の危険予測因子である", 膵臓, vol. 第35巻，第3号, JPN6022006214, 2020, pages 266, ISSN: 0005711816 * |
| 白井俊光: "CLEC-2/Podoplaninによる血小板の癌進展機構", 日本血栓止血学会誌, vol. 31, no. 4, JPN6022006206, 2020, pages 452 - 459, ISSN: 0005711810 * |
| 長田誠: "血中ｓＣＬＥＣ−２測定法の臨床応用と実用化に向けた検討", 科学研究費助成事業 研究成果報告書 [ONLINE], JPN6022006212, 2016, ISSN: 0005711814 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116761895A (zh) | 2023-09-15 |
| US20240288435A1 (en) | 2024-08-29 |
| EP4279606A1 (en) | 2023-11-22 |
| EP4279606A4 (en) | 2024-12-18 |
| KR20230131222A (ko) | 2023-09-12 |
| WO2022154045A1 (ja) | 2022-07-21 |
| JP7808059B2 (ja) | 2026-01-28 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20240205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241021 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241021 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251211 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7808059 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |